# Mevo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mevo

- Industry: Healthcare IT
- Headquarters: Sao Paulo, Brazil
- Website: www.mevo.com.br
- Total disclosed funding: $40M
- Latest round: Series B (Nov 28, 2024)
- Investors on record: 8

## About

Nexodata do Brasil Ltda. is a Brazil-based company that develops innovative digital health solutions, focusing on streamlining healthcare processes for patients, providers, and pharmacies through its integrated platform. Founded in 2017 by Lucas Lacerda and Pedro Dias, Mevo Tecnologia Ltda. operates primarily in Brazil and has successfully raised funding through multiple rounds, including a venture funding from Prosus Ventures, Matrix Partners, Jefferson River Capital, and Floating Point. The company has completed a total of 7 funding deals without any reported pivots in its business strategy.

Mevo offers an integrated health platform designed to simplify healthcare experiences for patients, healthcare providers, and pharmacies. Their core products include Mevo Receita Digital, a digital prescription system that enables healthcare professionals to issue prescriptions electronically, and Mevo Farma, an online pharmacy service facilitating the purchase and delivery of medication. The platform specifically addresses challenges such as the cumbersome process of obtaining paper prescriptions, the need for medical histories, and the inconvenience of purchasing medications, particularly due to lost prescriptions. Mevo's services cater primarily to residents of the Greater São Paulo area, targeting a diverse user base that includes patients, doctors, hospitals, clinics, and pharmacies, aiming to make healthcare more accessible and efficient. Mevo generates revenue through transaction-based models that involve both direct-to-consumer sales and partnerships with healthcare providers and pharmacies. Their business model includes enabling healthcare professionals to utilize Mevo Receita Digital to streamline the prescription process, thereby increasing patient engagement and facilitating medication purchases through Mevo Farma. The transactions are characterized by direct sales from patients purchasing medications online or at partnered pharmacies. In this structure, healthcare providers may refer patients to the Mevo platform for prescription services, while pharmacies receive prescriptions digitally, ensuring a seamless experience for end users. The revenue streams are diversified, leveraging both the convenience offered to patients and the collaborative relationships built with healthcare partners.

Mevo aims to expand its product offerings and geographic reach in the coming years. The company is focused on designing new features for Mevo Receita Digital to enhance user experience and is exploring expansion into additional Brazilian markets beyond Greater São Paulo. The company will use the March 2026 funding to accelerate expansion of its digital prescription platform and strengthen integration across scheduling, pharmacy fulfillment, and pharmaceutical industry solutions.

## Funding rounds

- Series B, Nov 28, 2024, $5M — Prosus Ventures
- Series B, Sep 18, 2024, $20M — Matrix Partners, Jefferson River Capital, Floating Point, IKJ Capital
- Series A, Jul 14, 2022, $8.4M — Floating Point
- Series A, Jul 8, 2021, $6.7M — FIR Capital, Mercado Libre Fund, Floating Point, Hospital Israelita Albert Einstein

## Investors

- FIR Capital (https://capitalatlas.ai/funds/fir-capital) — Series A
- Mercado Libre Fund (https://capitalatlas.ai/funds/mercado-libre-fund) — Series A
- Floating Point (https://capitalatlas.ai/funds/floating-point) — Series A, Series B
- Hospital Israelita Albert Einstein — Series A
- Matrix Partners (https://capitalatlas.ai/funds/matrix-partners) — Series B
- Jefferson River Capital — Series B
- IKJ Capital (https://capitalatlas.ai/funds/ikj-capital) — Series B
- Prosus Ventures (https://capitalatlas.ai/funds/prosus-ventures) — Series B